22-iododocosanoic acid | 76998-89-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 22-iododocosanoic acid
• CAS: 76998-89-5
• 化学式: C₂₂H₄₃IO₂
• 分子量: 466.487
• InChiKey: UAOCZGUYONJJEM-UHFFFAOYSA-N

物化性质

• 熔点：
  71-72 °C
• 沸点：
  513.1±23.0 °C(predicted)
• 密度：
  1.151±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  10.4
• 重原子数：
  25
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  21-docosenoic acid 在 bis(cyclohexanyl)borane 、 sodium acetate 、 chloroamine-T 、 sodium iodide 作用下， 生成 22-iododocosanoic acid
  参考文献：
  名称：

  Syntheses of organic iodides via reaction of organoboranes with sodium iodide

  摘要：

  DOI：

  10.1021/jo00325a030

文献信息

• Radiohalogenation method
  申请人：Research Corporation

  公开号：US04450149A1

  公开（公告）日：1984-05-22

  Organoborane compounds are halogenated by reacting an organoborane with iodinemonochloride, brominemono-chloride or a halide salt in the presence of a mild oxidizing agent.

  有机硼化合物可通过将有机硼烷与碘单氯化物、溴单氯化物或卤化物盐在温和氧化剂的存在下反应，进行卤代反应。
• Gooch, E. E.; Kabalka, G. W., Synthetic Communications, 1981, vol. 11, # 7, p. 521 - 526
  作者：Gooch, E. E.、Kabalka, G. W.

  DOI：——

  日期：——
• KABALKA G. W.; GOOCH E. E., J. ORG. CHEM., 1981, 46, NO 12, 2582-2584
  作者：KABALKA G. W.、 GOOCH E. E.

  DOI：——

  日期：——
• GOOCH E. E.; KABALKA G. W., SYNTH. COMMUN., 1981, 11, NO 7, 521-525
  作者：GOOCH E. E.、 KABALKA G. W.

  DOI：——

  日期：——
• DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS
  申请人：Agrawal C. Mauli

  公开号：US20090123516A1

  公开（公告）日：2009-05-14

  Disclosed are medical devices comprising one or more surfaces, one or more SAM molecules attached to the one or more surfaces of the medical device, and one or more therapeutic agents attached to the one or more self-assembled monolayer molecules. Also disclosed are medical devices comprising one or more surfaces, one or more self-assembled monolayer molecules attached to the one or more surfaces of the medical device, one or more linkers comprising a first functional group and a second functional group, the first functional group attached to the self-assembled monolayer molecule and a therapeutic agent attached to the second functional group. The therapeutic agent may be attached to the SAM molecule via a linker. The present invention also concerns methods of administering a therapeutic agent to a subject, comprising contacting the subject with one of the medical devices set forth herein.